TP53 and lung adenocarcinoma: In a recent study of KRAS-mutated lung adenocarcinoma, objective response rates to ICI differed among tumours with STK11/LKB1 co-mutation, tumours with TP53 co-mutation, and tumours without such co-mutations [11].